Protagonist Therapeutics (PTGX) Cash from Financing Activities (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Cash from Financing Activities data on file, last reported at $23.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 104.26% year-over-year to $23.4 million; the trailing twelve-month figure through Mar 2026 stood at $34.8 million (up 15.61% YoY), and the FY2025 full-year result was $22.9 million, down 11.56% from the prior year.
• Cash from Financing Activities advanced to $23.4 million in Q1 2026, from $2.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $108.2 million in Q2 2023 to a low of $527000.0 in Q4 2023.
• A 5-year average of $15.4 million and a median of $5.7 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 99.46% in 2022 and surged 15807.65% in 2023, its largest moves.
• Tracing PTGX's Cash from Financing Activities over 5 years: stood at $553000.0 in 2022, then slipped by 4.7% to $527000.0 in 2023, then soared by 664.9% to $4.0 million in 2024, then declined by 29.62% to $2.8 million in 2025, then surged by 723.9% to $23.4 million in 2026.
• Business Quant data shows PTGX's Cash from Financing Activities at $23.4 million in Q1 2026, $2.8 million in Q4 2025, and $5.7 million in Q3 2025.